Clinical Trial Update: Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study for corneal collagen cross-linking in eyes with corneal ectasia after refractive surgery has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Ectasia

Drugs mentioned

• Corneal collagen cross-linking (CXL) therapy

Snippet

Sponsor: Glaukos Corporation | Conditions: Corneal Ectasia | Phase 3 | Status: WITHDRAWN